More recently, integration of CGM with continuous subcutaneous insulin infusion (CSII) devices (insulin pumps) has led to the development of algorithm-controlled pumps that suspend insulin delivery when a low glucose level is predicted to occur within the ensuing 30 min, as well as hybrid closed loop systems that can both suspend insulin delivery to prevent hypoglycemia and automatically administer additional insulin to correct hyperglycemia. Here, INS is linked to Hyperglycemia.